A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

NCT01306617 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis C Infection
Hepatitis C
Hepatitis C Virus

Interventions

DRUG: ABT-450
DRUG: ABT-333
DRUG: ribavirin
DRUG: ritonavir

Sponsor

AbbVie (prior sponsor, Abbott)